Contents

Part I  Biology of Renal Cell Carcinoma

1  The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies ................................................................. 3
   Laura S. Schmidt, Ramaprasad Srinivasan, and W. Marston Linehan

2  Molecular Biology of Clear Cell Renal Carcinoma ...................... 27
   William G. Kaelin Jr.

3  HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment ................................................................. 49
   W. Kimryn Rathmell

4  Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC .................. 69
   Brittany Bahamon and Sabina Signoretti

5  Molecular Characterization of Renal Cell Carcinoma .................. 91
   Bin Tean Teh, Leslie J. Farber, and Kyle Furge

Part II  Current and Future Molecular Targets for RCC

6  Targeting the VEGF Pathway in Renal Cell Carcinoma .............. 115
   Cristina Suarez and Brian I. Rini

7  Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma ........................................... 135
   C. Lance Cowey and Thomas E. Hutson

8  Research Translation and Personalized Medicine ....................... 161
   James Brugarolas
9 Epigenetic Targeting and Histone Deacetylase Inhibition in RCC .......................................................... 193
   Swathi Ramakrishnan and Roberto Pili

10 C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma ......................................................... 213
   Hema Vankayala, Patricia LoRusso, and Ulka Vaishampayan

11 Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies ................................................................. 239
   Sumanta Kumar Pal, Karen Reckamp, Hua Yu, and Robert A. Figlin

12 Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma ............................................................. 253
   E. Oosterwijk, A.B. Stillebroer, and P.F.A. Mulders

13 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials .................. 271
   Hyung L. Kim, Edwin M. Posadas, and Robert A. Figlin

14 Mechanisms of Resistance to VEGF-Directed Therapy and Implications for Future Trial Design ..................... 283
   James W. Mier

15 Vaccine-Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma ............... 305
   Johannes Vieweg

Index .................................................................................................................................................. 323
Renal Cell Carcinoma
Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
Figlin, R.A.; Rathmell, W.K.; Bloom, J. (Eds.)
2012, XII, 328 p., Hardcover
ISBN: 978-1-4614-2399-7